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Brain derived neurotrophic factor (BDNF) is one of the key proteins involved in modulating neuronal 
survival, differentiation and synaptic plasticity in the brain. The reduction of the BDNF concentration in 
different brain areas has been associated with dementia and cognitive decline. The study investigated the 
association of the five BDNF polymorphisms, rs 6265 (Val66Met), rs11030104, rs7934165, rs1519480 and 
rs56164415 (C270T), with cognitive impairment. Eighty-two patients with Alzheimer’s disease (AD) and 
49 patients with mild cognitive impairment (MCI), which presents a high risk condition for AD, were 
included. Diagnosis of AD was done according to the NINCDS-ADRDA and DSM-IV criteria. Cognitive 
impairment was evaluated using Mini-Mental Status Examination (MMSE) and Clock Drawing Test (CDT). 
After subdividing the subjects according to the different BDNF variants, association between rs1519480 
and MMSE scores in patients with AD (F=3.856; P=0.025) and MCI (F=3.270; P=0.047) was found. There 
was a marginal association of MMSE scores with C270T polymorphism in patients with AD (F=3.697; 
P=0.058). Similar results were obtained using CDT scores to predicts person's cognitive abilities, showing 
that AD patients differed significantly (F=4.666; P=0.034) in CDT scores when subdivided according to the 
rs1519480 genotype, while this association was marginally significant in individuals with MCI (F=3.904; 
P=0.054). We have also found an association of rs11030104 with CDT scores in AD (F=5.495; P=0.022). 
Other analysed polymorphisms were not significantly associated with MMSE or CDT scores. These results 
reveal that BDNF rs1519480 and rs11030104 polymorphisms were significantly associated with cognitive 
decline in patients with AD or MCI. 
 
